Back

Benefit and Harm of Extended Dual Antiplatelet Therapy After PCI in high-risk TWILIGHT-like patients with acute coronary syndrome

14 March 2021 (12:00 - 13:00)
Organised by:
Congress Presentation Part of: Live Abstract session - Antithrombotics and bleeding Treatment ACVC Premium Access ACVC 2021

About the speaker

Photo
Doctor Hao-Yu Wang

Fuwai Hospital, CAMS and PUMC, Beijing (China)

7 More presentations in this session

Presentation thumbnail
Trends in major bleeding events in patients with acute coronary syndrome.
Doctor A. Cordero (Alicante, ES)
Abstract
Presentation thumbnail
Long-term ischemic and bleeding risk with extended dual antiplatelet therapy after PCI in patients with 2018 ESC/EACTS myocardial revascularization guideline-endorsed high thrombotic risk features.
Doctor H. Wang (Beijing, CN)
Abstract
Presentation thumbnail
Safety and efficacy of direct oral anticoagulants (DOACs) vs warfarin in patients with concurrent atrial fibrillation and bioprosthetic mitral or aortic valve replacement-a meta analysis
Ms A. Abdul Razzack (Hyderabad, IN)
Abstract
Presentation thumbnail
Cardiovascular outcomes of clopidogrel and aspirin vs ticagrelor and aspirin in geriatric population with acute coronary syndrome-a systematic review and meta analysis
Ms A. Abdul Razzack (Hyderabad, IN)
Abstract
Presentation thumbnail
The efficacy and safety of prolonged dual antiplatelet therapy beyond 12 months in patients with high risk of ischemic or bleeding events after PCI
Doctor H. Wang (Beijing, CN)
Abstract

Access the full session

Session thumbnail
Live Abstract session - Antithrombotics and bleeding

The Event

Event poster

ACVC 2021

14 March 2021 12:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources